Boehringer Ingelheim Invests US$188 Million in Xochimilco Plant

Boehringer Ingelheim will invest MX$3.5 billion (US$188 million) to expand and modernize its pharmaceutical plant in Xochimilco, says the company in a press release. The project aims to make the facility the largest tablet production site within the Boehringer group, surpassing plants in Spain, China, Japan, Greece, and Germany. This investment supports supply to the Mexican market and exports to over 40 countries.

“For over 70 years, Boehringer Ingelheim has believed in Mexico and its people. This investment is a commitment to national talent. We expect to generate 1,800 direct jobs and more than 15,000 indirect jobs, with the goal of manufacturing 5 billion tablets from Xochimilco,” says Augusto Muench, President for Mexico, Central America, and the Caribbean, Boehringer Ingelheim.

The plant in Xochimilco produces antihypertensive and antidiabetic drugs. The company plans to increase output while aligning with regulatory requirements from COFEPRIS, the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and other agencies in export markets. The investment also aims to improve supply chain traceability and transparency under a compliance framework designed to uphold ethical and quality standards.

The announcement came amid a broader set of pharmaceutical investments supported by the Mexican government’s Plan México. The plan includes over MXS12 billion in investments from three multinational companies and one domestic firm. According to David Kershenobich, Minister of Health, these efforts aim to strengthen the health system by fostering innovation, enhancing manufacturing capacity, expanding clinical research, digitizing processes, and creating specialized jobs.